Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Levine, Gary M. , M.D..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Hologic, Inc.
Information provided by (Responsible Party):
Gary M Levine, M.D., Levine, Gary M. , M.D.
ClinicalTrials.gov Identifier:
NCT01379092
First received: June 2, 2011
Last updated: March 15, 2012
Last verified: March 2012
  Purpose

The objective of this study is to evaluate the image quality and operation of a self-contained direct digital radiography system for breast specimen imaging.


Condition Intervention
Breast Cancer
Device: Trident Specimen Radiography System
Device: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

Resource links provided by NLM:


Further study details as provided by Levine, Gary M. , M.D.:

Primary Outcome Measures:
  • Breast biopsy specimen will be imaged on standard of care device and on the Trident Specimen Radiography device to compare quality of images. [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
    Images will be taken at time of biopsy with no additional follow-up time for patient.


Secondary Outcome Measures:
  • Device Operation [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
    Device will be evaluated for length of time to carry out procedure, ease of use in patient data entry, procedure selection, taking the exposure, usability and usefulness of image manipulation tools and overall rating.


Estimated Enrollment: 100
Study Start Date: June 2011
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Breast biopsy specimen imaging & comparison of image quality
Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
Device: Trident Specimen Radiography System
MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
Device: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.

  Hide Detailed Description

Detailed Description:

Specimen imaging is an accepted method for evaluating tissue specimens which are obtained either through minimally-invasive breast needle biopsy (MIBB) or breast surgery. Specimen imaging is used to confirm the targeting and sampling adequacy of radiographically apparent breast abnormalities. Specimen images are acquired and then compared to the routine and diagnostic imaging to provide radiographic evidence that the index lesion was adequately targeted and sampled (as in the case of MIBB) or targeted and removed with adequate margins [as in the case of breast surgical specimens (BSS)]. Specimen imaging also provides guidance to the histopathologist when evaluating the breast specimen.

Near real-time image acquisition, review and feedback is essential for specimen imaging. The patient typically remains in compression on the biopsy table for MIBB or under anesthesia for BSS until the clinician has confirmation that the index abnormality has been adequately sampled (in the case of MIBB) or surgically excised. For this reason, digital techniques are favored over analog (film) counterparts because of the immediacy of image acquisition and transfer and display to the radiologist for review.

Image quality and speed are critical factors in specimen imaging. High resolution images are a clinical requirement to delineate the features and extent of mass lesions, and presence and extent of microcalcifications.

Conventional full-field digital (FFDM) mammographic equipment located in the mammography department is one accepted approach for specimen imaging. An advantage of this method is that a licensed and skilled mammographic technologist assures the adequate exposure of specimens. However, this method requires that the FFDM system be free at the time the specimen arrives in the mammography department, interfering with mammogram schedules. In the case of BSS, the use of conventional FFDM systems additionally requires the transport of specimens to the mammography department, adding significant time that the patient is under anesthesia.

Another mode for specimen radiography is self-contained digital radiography specimen imaging systems that are located in the mammography department or in the Operating Room (intraoperative). The use of self-contained digital systems frees the conventional mammography system for its intended purpose, while providing the clinician all the speed of digital radiography.

It has been shown that intraoperative imaging significantly reduces the amount of time that the patient is under anesthesia.

Although, self-contained digital radiography specimen imaging systems provide an advantage in speed, resulting images may suffer in image quality and despite the availability of intraoperative self contained systems, many clinicians choose to transfer specimens to the mammography department for imaging on a conventional FFDM system. Current specimen radiography systems employ an indirect digital technique, a two step conversion, where incoming x-ray signal is converted to light and then to digital signal. The intermediate step of converting signal to light, leads to diffusion and scatter over many pixels and this in turn leads to degradation of the very fine features of mass densities and microcalcifications.

Direct Digital technique is another method currently used in breast imaging. The direct digital technique has the advantage of converting incoming signal directly to digital signal, avoiding the intermediary light conversion phase of indirect exposure. The direct to digital process results in better use of incoming signal and greater resolution and thus a sharper image, providing high resolution of minute features associated with mass lesions and microcalcifications.

Another common characteristic of current self-contained systems is the use of "stitching" many small CMOS chips to create a larger image detector. This type of tiling provides for a more economical system, but shearing effects, gaps between chips and overall concerns with calibration of multiple chips significantly degrades image quality.

All digital images, indirect or direct are acquired in a raw state and processed to allow review. While image processing cannot improve or change the raw aspects of the image after acquisition, processing can improve the visibility of features available in the image. Image processing is fundamentally associated with image acquisition technique. If the image is not adequately exposed, image processing will not be optimally applied and in some cases fail, requiring additional imaging.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Breast specimens acquired through MIBB or Surgical techniques arriving for specimen imaging

Exclusion Criteria:

  • Breast specimens that are larger than12 x 14 cm.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01379092

Contacts
Contact: Gary M. Levine, M.D. 949-764-5780 gary.levine@hoag.org
Contact: Cheryl M. Hanna, R.N. 949-764-4537 cheryl.hanna@hoag.org

Locations
United States, California
Hoag Memorial Hospital Presbyterian Recruiting
Newport Beach, California, United States, 92658
Sponsors and Collaborators
Levine, Gary M. , M.D.
Hologic, Inc.
Investigators
Principal Investigator: Gary M. Levine, M.D. Hoag Memorial Hospital Presbyterian
  More Information

Publications:
Responsible Party: Gary M Levine, M.D., Director of Breast Imaging, Levine, Gary M. , M.D.
ClinicalTrials.gov Identifier: NCT01379092     History of Changes
Other Study ID Numbers: 2011-01-LEV
Study First Received: June 2, 2011
Last Updated: March 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Levine, Gary M. , M.D.:
Radiography
Breast Specimen Imaging

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 25, 2014